INDIA – Sun Pharma has reached an agreement with Aksigen Hospital Care to acquire three of its anti-inflammatory brands: ‘Disperzyme’, ‘Disperzyme-CD’, and ‘Phlogam’.
The three brands include Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg).
The fixed-dose combination of Tryspin, Bromelain, and Rutoside will be available to patients with postoperative inflammation who are undergoing minor surgery and dental procedures.
In a press release, Sun Pharma said: “All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.”
Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain, and Rutoside (TBR) to complete a clinical study in India and get DCGI approval.
The brands, which were registered and launched in India by Aksigen in 2013, complement each other’s actions and provide a more well-rounded control of the inflammatory process.
The fixed-dose combination of Tryspin, Bromelain, and Rutoside is indicated for the treatment of a wider range of processes involved in inflammation, a response triggered by damage to living tissues.
“TBR, the systemic enzyme-flavonoid therapy, intervenes in different processes: the release of inflammatory mediators, the modulation of adhesion molecules, and the activation of fibrinolysis with consequently improved healing,” the company noted.
The acquisition of these three brands will expand Sun Pharma’s anti-inflammatory product portfolio in India.
It will also strengthen its presence in India’s overall market of proteolytic enzyme for healing, pain, and edema valued at approximately US$6M (Rs.500 crores).
The company claims that the acquisition is in line with Sun Pharma’s vision to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices.
Commenting on the unique agreement with Aksigen, Kirti Ganorkar, Chief Executive Officer (CEO) of India Business, Sun Pharma, emphasized: “The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio.”
He outlined that introducing the systemic enzyme therapy combination in India at an affordable price will help improve patient access to medications for treating edema.
“In a comparative clinical trial in India, the brands provided significantly better control and resolution of postoperative pain and inflammation,” Ganorkar said.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
